The recommended dose of Eylea for advanced wet age-related macular degeneration is 2 milligrams every four weeks for the first 12 weeks, followed by 2 milligrams every two months, according to the American Macular Degeneration Foundation. Eylea is a form of anti-VEGF therapy.
Anti-VEGF therapy is the most effective treatment for advanced wet age-related macular degeneration, as of 2015, states the AMDF. Anti-VEGF therapy consists of periodic injections of a chemical called Anti-VEGF directly into the eye. Vascular endothelial growth factor, or VEGF, is a naturally-occurring protein in humans that promotes growth of new blood vessels. However, VEGF can also create abnormal blood vessels in the eye, resulting in eye damage.